Cleveland Clinic became one of six healthcare institutions to join a pilot program with the goal of standardizing and collecting data on rare musculoskeletal tumors to advance sarcoma research. One year after the cohort assembled, they are now reflecting on lessons learned and scaling their initiative nationwide.